You are here

Enhanced Membranes for Active Mixing Oxygenators

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N/A
Agency Tracking Number: 1R43HL065834-01A1
Amount: $110,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2001
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
325 WATER ST
WILMINGTON, DE 19804
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 NINA LAMBA
 () -
Business Contact
Phone: (302) 999-7996
Email: SNEMSER@COMPACTMEMBRANE.COM
Research Institution
N/A
Abstract

Historically blood oxygenators for short-term by-pass surgery or newly developing long-term strategies use systems that are liquid side mass transfer, limited. Long-term therapies require non-porous coatings to limit blood oxygenator wet out. Design advances led to improved fluid dynamics which enhanced mass transfer. In these later systems membrane transport limitations now are major limitations. Compact Membrane Systems (CMS) developed non-porous membranes for long-term blood oxygenation. This CMS first generation blood oxygenation technology produces membranes with 150 cc/min-m2 oxygen transport. With more compact second generation systems there is need for higher flux non-porous membranes. CMS has identified novel routes to improve membrane oxygen transport ten-fold. This improvement in oxygen transport should be sufficient to meet need of improved fluid dynamics second generation products. These new systems should also significantly improve fabrication economics. In Phase I CMS will develop membranes for blood oxygenation with a five-fold improvement in flux. These novel membranes will demonstrate improved fluid dynamics and significantly enhance overall system performance. Animal studies with detailed methodology are included in this program. Membrane integrity will be verified at the end of the tests. PROPOSED COMMERCIAL APPLICATIONS: This technology will broadly enhance the capability for both long-term and short-term blood gas exchange. Therefore it should be of value for long-term treatments for ARDS, ECMO and artificial lung as well as conventional by-pass surgery.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government